| 產(chǎn)品名稱： |
(1R)-(S)-蒎烷二醇 1-氨基-3-甲基丁烷-1-硼酸三氟乙酸鹽 |
| 中文別名： |
(aR,3aS,4S,6S,7aR)-六氫-3a,8,8-三甲基-alpha-(2-甲基丙基)-4,6-甲橋-1,3,2-苯并二氧硼烷-2-甲胺 2,2,2-三氟乙酸鹽;(αR)-(1S,2S,3R,5S)-蒎烷二醇-1-氨基-3-甲基丁烷-1-硼酯三氟醋酸鹽;(1R)-(s)-蒎二醇 1-三氟乙酸銨-3-甲基丁烷-1-硼;(aR,3aS,4S,6S,7aR)-六氫-3a,8,8-三甲基-alpha-(2-甲基丙基)-4,6-甲橋-1,3,2-苯并二氧硼烷;C.I.直接紅227;硼替佐米中間體;硼替佐米中間體1;硼替佐米中間體A;(ALPHAR,3AS,4S,6S,7AR)-六氫-3A,8,8-三甲基-ALPHA-(2-甲基丙基)-4,6-甲撐-1,3,2-苯并二氧雜BOROLE-2-甲胺 2,2,2-三氟乙酸酯;(R)-1-氨基-3-甲基丁基硼酸蒎烷二醇酯三氟醋酸鹽;(R)-六氫-三甲基-(2-甲基丙基)-甲橋-苯并二氧硼烷-甲胺-三氟乙酸鹽;AR,3AS,4S,6S,7AR)-六氫-3A,8,8-三甲基-ALPHA-(2-甲基丙基)-4,6-甲橋-1,3,2-苯并二氧硼烷-2-甲胺 2,2,2-三氟乙酸鹽,保特佐米(硼替佐米)中間體;氟乙酸鹽;中間體5;硼替佐米中一;硼替佐咪中間體;硼替佐米三氟乙酸鹽中間體;保特佐米(硼替佐米)中間體;BORTEZOMIB中間體;(AR,3AS,4S,6S,7AR)-六 |
| 英文別名： |
(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate;(R)-BoroLeu-(+)-Pinanediol trifluoroacetate;(1R)-(S)-Pinanediol 1-ammonium trifluoroacetate-3-methylbutane-1-boronate;(1R)-(S)-PINANEDIOL-1-AMINO-3-METHYLBUTANE-1-BORONATE, TRIFLUOROACETATE;(R)-BoroLeu-(+)-Pinanediol-CF3COOH;(R)-BoroLeu-(+)-pinanediol-trifluoroacetate;(R)-Boroleucine-(1S,2S,3R,5S)-(+)-pinanediol ester trifluoroacetate;(αR)-(1S,2S,3R,5S)-P;(αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate;(αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetic Acid Salt;(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate;Bortezomib INT A;(αR,3aS,4S,6S,7aR)-;Ixazomib intermediate;Bortezomib Intermediates;Bortezomib Intermediate 1;Bortezomib Intermediate A;Pinanedioltrifluoroacetate salt-;(R)-BoroLeu-(+)-Pinanediol-CF3CO2H;(R)-BoroLeu-(+)-Pinanediol-CF3COOH N-4;(R)-3-METHYL-1-((3AS,4S,6S,7AR)-3A,5,5-TRIMETHYLHEXAHYDRO-4,6-METHANOBENZO[D][1,3,2]DIOXABOROL-2-YL)BUTAN-1-AMINE 2,2,2-TRIFLUOROACETATE;(1R)-(S)-Pinanediol 1-ammoni |
| CAS號(hào)： |
179324-87-9 |
| 分子式： |
C17H29BF3NO4 |
| 分子量： |
379.2227 |
| 純度： |
99% |
微信客服
QQ客服
